deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04927780

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer (PREOPANC-3)

Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 Study

Sponsor: Dutch Cancer Society

Conditions Pancreatic Cancer Pancreatic Ductal Adenocarcinoma Resectable Pancreatic Adenocarcinoma
Interventions Fluorouracil Irinotecan Hydrochloride Leucovorin Calcium Oxaliplatin Resection
Updated 13 times since 2021 Last updated: Aug 27, 2024 Started: Sep 7, 2021 Primary completion: Feb 28, 2026 Completion: Jul 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, this trial is actively recruiting participants. The trial is conducted by Dutch Cancer Society and has accumulated 13 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Feb 2023 · 7 months · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Sep 2023 · 4 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  3. Sep 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  4. May 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  5. Feb 2023 — May 2023 [monthly]

    Recruiting PHASE3

▶ Show 8 earlier versions

  1. Jul 2022 — Feb 2023 [monthly]

    Recruiting PHASE3

  2. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  3. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  4. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  5. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  6. Nov 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  7. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  8. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dutch Cancer Society
  • Dutch Pancreatic Cancer Group
  • Erasmus Medical Center
Data source: Erasmus Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Amersfoort, Netherlands , Amsterdam, Netherlands , Breda, Netherlands , Deventer, Netherlands , Eindhoven, Netherlands , Enschede, Netherlands , Gothenburg, Sweden , Groningen, Netherlands , Heerenveen, Netherlands and 10 more locations